UnknownPhase 1NCT02296983
A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Oxford
- Principal Investigator
- Philip Bejon, MD, PhDKEMRI-Wellcome Trust Collaborative Research Program
- Intervention
- VSV-ZEBOV(biological)
- Enrollment
- 40 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2014 – 2016
Study locations (1)
- KEMRI Wellcome Trust Research Programme, Kilifi, Coast, Kenya
Collaborators
World Health Organization · Wellcome Trust · Institute of Tropical Medicine, University of Tuebingen · Albert Schweitzer Hospital · Philipps University Marburg · Universitätsklinikum Hamburg-Eppendorf · University Hospital, Geneva
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02296983 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University